## Balazs Szamosfalvi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6950131/publications.pdf Version: 2024-02-01



RALAZS SZAMOSEALVI

#	Article	IF	CITATIONS
1	Deployment of a New CRRT/PIRRT Device during the COVID-19 Pandemic Emergency: Organizational Challenges and Implementation Results. Blood Purification, 2021, 50, 390-398.	1.8	4
2	Technology Innovations in Continuous Kidney Replacement Therapy: The Clinician's Perspective. Advances in Chronic Kidney Disease, 2021, 28, 3-12.	1.4	2
3	Management of dysnatremias with continuous renal replacement therapy. Seminars in Dialysis, 2021, 34, 472-479.	1.3	14
4	Regional citrate anticoagulation "non-shock―protocol with pre-calculated flow settings for patients with at least 6 L/hour liver citrate clearance. BMC Nephrology, 2021, 22, 244.	1.8	10
5	Citrate Anticoagulation for Continuous Kidney Replacement Therapy: An Embarrassment of RICH-es. American Journal of Kidney Diseases, 2021, 78, 146-150.	1.9	4
6	Regional Citrate Anticoagulation Protocol for Patients with Presumed Absent Citrate Metabolism. Kidney360, 2021, 2, 192-204.	2.1	14
7	Innovations in CKRT: individualized therapy with fewer complications. Nature Reviews Nephrology, 2020, 16, 560-561.	9.6	3
8	Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory Therapy. ASAIO Journal, 2020, 66, 1079-1083.	1.6	28
9	Cell-Based Therapies. , 2019, , 1190-1193.e1.		0
10	High sodium continuous venoâ€venous hemodialysis with regional citrate anticoagulation and online dialysate generation in patients with acute liver failure and cerebral edema. Hemodialysis International, 2018, 22, 184-191.	0.9	11
11	Continuous Renal Replacement Therapy for the Management of Acid-Base and Electrolyte Imbalances in Acute Kidney Injury. Advances in Chronic Kidney Disease, 2016, 23, 203-210.	1.4	36
12	Immunomodulatory Device Promotes a Shift of Circulating Monocytes to a Less Inflammatory Phenotype in Chronic Hemodialysis Patients. ASAIO Journal, 2016, 62, 623-630.	1.6	18
13	Online Hemoglobin and Oxygen Saturation Sensing During Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation. ASAIO Journal, 2015, 61, 489-495.	1.6	6
14	Treatment of Severe Metabolic Alkalosis with Continuous Renal Replacement Therapy. ASAIO Journal, 2015, 61, e20-e25.	1.6	4
15	A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury. PLoS ONE, 2015, 10, e0132482.	2.5	47
16	Treatment of Severe Hyponatremia in Patients With Kidney Failure: Role of Continuous Venovenous Hemofiltration With Low-Sodium Replacement Fluid. American Journal of Kidney Diseases, 2014, 64, 305-310.	1.9	44
17	Considerations in the Critically III ESRD Patient. Advances in Chronic Kidney Disease, 2013, 20, 102-109.	1.4	10
18	Sensors and Hybrid Therapies: A New Approach with Automated Citrate Anticoagulation. Blood Purification, 2012, 34, 80-87.	1.8	19

BALAZS SZAMOSFALVI

#	Article	IF	CITATIONS
19	Development of an online citrate/Ca <sup>2+</sup> sensing system for dialysis. Analyst, The, 2011, 136, 317-320.	3.5	8
20	Automated Regional Citrate Anticoagulation: Technological Barriers and Possible Solutions. Blood Purification, 2010, 29, 204-209.	1.8	35
21	α-Endosulfine in Diabetic Nephropathy. , 2006, , 305-313.		0
22	Rat mesangial α-endosulfine. Kidney International, 2004, 65, 1731-1739.	5.2	7
23	A New Mesangial Triumvirate: Sulfonylureas, Their Receptors and Endosulfines. Nephron Experimental Nephrology, 2002, 10, 1-6.	2.2	1
24	Putative subunits of the rat mesangial KATP: A type 2B sulfonylurea receptor and an inwardly rectifying K+ channel. Kidney International, 2002, 61, 1739-1749.	5.2	21
25	Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Kidney International, 1999, 55, 2289-2298.	5.2	9